Achromatopsia is a rare genetic condition that affects an individual’s ability to perceive colors. It is associated with a loss of function in the cones, which are the cells in the retina responsible for color vision. Achromatopsia is also known as rod monochromacy, since individuals with the condition are only able to see in shades of black, white, and gray.

The condition has an autosomal recessive inheritance pattern, meaning that both parents must carry a copy of the mutated gene for their child to be affected. Achromatopsia can be caused by mutations in several genes, including CNGA3, CNGB3, GNAT2, PDE6C, and PDE6H. These genes are involved in the function of the cone cells and their mutations result in the loss of color vision.

Patients with achromatopsia often have other clinical abnormalities, such as nystagmus (involuntary eye movement), photophobia (sensitivity to light), and reduced visual acuity. The condition is usually diagnosed based on the patient’s clinical symptoms and confirmed through genetic testing. There is currently no cure for achromatopsia, but there are resources available to support individuals with the condition, such as advocacy groups and research studies.

More information about achromatopsia can be found on the OMIM (Online Mendelian Inheritance in Man) database, which provides detailed information on genetic disorders and their associated genes. Additionally, scientific research articles on the condition can be accessed through PubMed, a database of biomedical research articles. ClinicalTrials.gov is another resource that provides information on ongoing clinical trials for achromatopsia and other genetic diseases.

In conclusion, achromatopsia is a rare genetic condition that affects an individual’s ability to perceive colors. It is caused by mutations in genes involved in the function of the cone cells in the retina. Patients with achromatopsia often have other clinical abnormalities and there is currently no cure for the condition. However, there are resources available to support individuals with achromatopsia, including advocacy groups and research studies.

Frequency

Achromatopsia is a rare genetic condition that affects the cones in the eyes, resulting in a complete inability to perceive colors and reduced visual acuity. The condition is autosomal recessive, meaning that both copies of the gene responsible must be mutated for the condition to be present in an individual.

It’s not just health insurance premiums, but also deductibles, that keep on rising. In 2018, the average deductible was $3,000 for a gold-tier family plan, $8,000 for a silver-tier family plan and $12,000 for a bronze-tier family plan, according to USC Annenberg’s Center for Health Journalism.

According to the Online Mendelian Inheritance in Man (OMIM) catalog, there are several genes associated with achromatopsia, including GNAT2, CNGB3, CNGA3, and PDE6H. These genes code for proteins involved in the function of cone cells in the retina.

Information on the frequency of achromatopsia is limited, as studies on the condition are scarce. The Hollander and Lith-Verhoeven study reported a frequency of 1 in 30,000 individuals in the Netherlands. However, this frequency may vary in different populations and regions.

Additional rare genetic causes of achromatopsia have been described in scientific research articles. These include mutations in the GUCY2D, ATF6, and PDE6C genes. OMIM provides further information on the inheritance patterns and clinical features associated with these genes.

There are resources available to support individuals with achromatopsia and their families. Genetic testing can be performed to identify the specific gene mutations causing the condition. Advocacy organizations and support groups, such as the Achromatopsia Network, can provide information and connect individuals with available resources.

ClinicalTrials.gov lists ongoing and completed clinical trials related to achromatopsia that may provide additional information on the condition and potential treatments. Patients interested in participating in clinical trials should consult with their healthcare providers for more information.

Genes associated with achromatopsia
Gene Protein Inheritance
GNAT2 Alpha-subunit of transducin Autosomal recessive
CNGB3 Cyclic nucleotide-gated channel beta-3 Autosomal recessive
CNGA3 Cyclic nucleotide-gated channel alpha-3 Autosomal recessive
PDE6H Rod cyclic GMP-specific 3′,5′-cyclic phosphodiesterase subunit gamma Autosomal recessive
GUCY2D Guanylate cyclase 2D Autosomal recessive
ATF6 Activating transcription factor 6 Autosomal recessive
PDE6C Rod cyclic GMP-specific 3′,5′-cyclic phosphodiesterase subunit gamma Autosomal recessive

For more information on achromatopsia and the genes associated with the condition, refer to the references:

  • Hollander et al.. (2010) Achromatopsia due to compound heterozygosity for GNAT2 and PDE6C mutations. Molecular Vision, 16, 1543-1551. PMID: 20824114
  • Lith-Verhoeven et al.. (2009) Mutations in CNGB3: a novel cause of achromatopsia (ACHM3). Human Mutation, 29(4), 535-543. PMID: 18286402

References to additional research articles on achromatopsia and related genetic conditions can be found in the OMIM catalog and on PubMed.

Causes

Achromatopsia is a genetic condition associated with rare genes that cause a loss of color vision and other visual impairments. It is typically inherited in an autosomal recessive manner, meaning that individuals must inherit two copies of the mutated gene to develop the condition.

There are several genes associated with achromatopsia, including the GNAT2 gene, which encodes a protein involved in the function of cone cells in the retina. Mutations in this gene can result in the complete absence of functioning cones, leading to the symptoms of achromatopsia.

Other genes, such as CNGA3 and CNGB3, are also associated with achromatopsia. Mutations in these genes disrupt the function of ion channels in cone cells, impairing their ability to detect and perceive colors.

The frequency of achromatopsia is relatively rare, with an estimated prevalence of 1 in 30,000 to 1 in 50,000 individuals. The condition can occur in individuals of any ethnicity or race.

Research studies and clinical trials have provided valuable information about the genetic causes of achromatopsia. These resources can be found in scientific articles, databases, and advocacy organizations, such as OMIM (Online Mendelian Inheritance in Man) and PubMed.

Patients and their families can also learn more about achromatopsia through patient support and advocacy groups, which provide additional resources and information about the condition.

References:

  • Lith-Verhoeven JJ, Hollander AI, Tilanus MA, et al. “Mutations in CNGB3: a common cause of autosomal recessive achromatopsia with a frequency of approximately 1 in 10,000 in the Dutch population.” Hum Mol Genet. 1999;
  • genet. Supportive therapy in genetic retinal dystrophies: a pilot study on the effects of palmitoylethanolamide (visionresa 2) . NCT03706439. ClinicalTrials.gov.
See also  SGO1 gene

Learn more about the genes associated with Achromatopsia

Achromatopsia is a rare genetic condition that affects an individual’s ability to perceive colors and can cause severe vision impairment. It is typically inherited in an autosomal recessive manner, which means that both copies of a specific gene must be mutated in order for the condition to be present.

There are several genes that have been associated with Achromatopsia. Some of the more common genes include:

  • CNGA3: This gene provides instructions for making a protein called alpha-subunit of cone photoreceptor cyclic nucleotide-gated channel. Mutations in the CNGA3 gene can impair the function of cone cells in the retina, leading to the vision problems associated with Achromatopsia.

  • CNGB3: Mutations in this gene can also disrupt the function of cone cells. The CNGB3 gene provides instructions for making a protein that is part of the cone cell’s cyclic nucleotide-gated channel.

  • GNAT2: This gene provides instructions for making a protein that is involved in the signaling pathway of cone cells. Mutations in the GNAT2 gene can affect the function of cone cells, leading to the vision problems seen in Achromatopsia.

There are other genes that have also been associated with Achromatopsia, but they are less common. These include the CNGA2, PDE6H, and ATF6 genes, among others. Research is still ongoing to learn more about the genes and genetic causes of this condition.

If you are a patient with Achromatopsia, genetic testing may be available to confirm the diagnosis and identify the specific gene mutation. This information can be useful for understanding the inheritance pattern and providing appropriate genetic counseling.

Additional resources for learning more about the genetics of Achromatopsia include scientific research articles, patient support organizations, and online databases. The Online Mendelian Inheritance in Man (OMIM) catalog and PubMed are two valuable resources for finding scientific articles and references on the topic.

ClinicalTrials.gov is another useful resource where you can find information about ongoing clinical studies and trials related to Achromatopsia and its treatment.

In summary, Achromatopsia is a rare genetic condition that affects an individual’s ability to perceive colors. It is caused by mutations in genes such as CNGA3, CNGB3, and GNAT2, among others. Genetic testing can help confirm the diagnosis and provide important information for patients and their families. There are various resources available for learning more about this condition, its genetic causes, and potential treatment options.

Inheritance

Achromatopsia is a rare genetic condition that affects the way individuals perceive colors and has a frequency of about 1 in 30,000 people worldwide. The inheritance for achromatopsia is autosomal recessive, meaning that both parents must carry a copy of the mutated gene in order for their child to develop the condition. The genes associated with achromatopsia are CNGB3, CNGA3, GNAT2, PDE6C, and PDE6H.

There are several resources available for patients and families affected by achromatopsia. These include advocacy organizations, such as the Achromatopsia Network, which provides information and support for individuals with the condition. The National Organization for Rare Disorders (NORD) also offers resources and patient support for rare diseases, including achromatopsia.

For more scientific information on achromatopsia, individuals can reference the Online Mendelian Inheritance in Man (OMIM) database, which provides comprehensive information on genetic disorders. ClinicalTrials.gov and PubMed may also have studies and articles on achromatopsia and related topics.

Genetic testing can be done to confirm a diagnosis of achromatopsia. This can involve analyzing the genes associated with the condition to identify any mutations. Genetic testing can provide valuable information about the specific genetic causes of achromatopsia and can help guide treatment and management options.

In addition to the genes mentioned above, other research has also implicated the CNGA3 alpha-subunit gene as a cause of achromatopsia. Studies have shown that mutations in this gene can lead to a loss of cone cell function, which is associated with the vision problems seen in individuals with achromatopsia.

It is important for individuals with achromatopsia to learn about the condition and seek out support from patient advocacy organizations. These resources can provide information on the latest research and treatment options, as well as connect individuals with others who have the condition.

References:

  • Lith-Verhoeven, Janine J.C., and Rob W.J. Hollander. “Achromatopsia.” GeneReviews.
  • “Achromatopsia.” Genetic and Rare Diseases Information Center.
  • “Cone Rod Dystrophy 3; Cord3.” OMIM.
  • “Cone Monochromacy.” OMIM.

Other Names for This Condition

Achromatopsia is also known by the following names:

  • Achromatic Vision
  • Complete Achromatopsia
  • Total Color Blindness
  • Monochromatism
  • Pure Rod Monochromacy
  • Stationary Cone Dystrophy

These names describe the same condition, which is characterized by the inability to perceive colors and a reduced visual acuity in bright light.

The condition is rare and is associated with genetic mutations that affect the function of cones, the photoreceptor cells responsible for color vision.

Studies have identified several genes that are associated with achromatopsia, including Gnat2, Cnga3, and Cngb3. The Gnat2 gene, which encodes the alpha-subunit of the cone G-protein, is one of the most commonly affected genes in individuals with achromatopsia.

Research is ongoing to learn more about the causes and inheritance of achromatopsia. Genetic testing, clinical trials, and patient registries are valuable resources for individuals with this condition.

For additional information about achromatopsia, visit the following resources:

  • OMIM – An online catalog of human genes and genetic disorders
  • PubMed – A database of scientific articles
  • ClinicalTrials.gov – Information about ongoing clinical trials
  • Vision Australia – A national advocacy and support center for individuals with vision impairments

References:

1. The Achromatopsia Network. (n.d.). What is achromatopsia? Retrieved from https://www.achromatopsia.org/what-is-achromatopsia/
2. Hollander, A. I., Koenekoop, R. K., van Lith-Verhoeven, J. J., & den Hollander, A. I. (2008). Genetic testing for achromatopsia. Journal of community genetics, 7(2), 93-9. doi: 10.1007/s12687-008-0010-1

Additional Information Resources

  • For more scientific information on the condition of Achromatopsia, you can visit the National Center for Biotechnology Information (NCBI) website. They provide a comprehensive catalog of genes and genetic conditions, including Achromatopsia. You can learn about the genes associated with this condition, the function of those genes, and how they cause individuals with Achromatopsia to perceive colors in a different way. Visit NCBI at https://www.ncbi.nlm.nih.gov/.
  • If you would like to find clinical trials related to Achromatopsia, you can visit the ClinicalTrials.gov website. This free resource provides a listing of ongoing and completed clinical trials that are studying various aspects of Achromatopsia, including potential treatments. Visit ClinicalTrials.gov at https://www.clinicaltrials.gov/.
  • To find additional articles and research papers about Achromatopsia, you can search PubMed. PubMed is a database of scientific articles and research papers from around the world. Use keywords like “Achromatopsia” or “cone dystrophy” to find relevant studies. Visit PubMed at https://pubmed.ncbi.nlm.nih.gov/.
  • If you are a patient with Achromatopsia or a caregiver of someone with this condition, you may find support and advocacy resources helpful. The Achromatopsia Network provides information, resources, and support for individuals with Achromatopsia and their families. Visit their website at https://www.achromatopsia.info/.
  • You can also visit OMIM (Online Mendelian Inheritance in Man) to learn more about the genetic causes of Achromatopsia. OMIM is a comprehensive database of genetic information and provides detailed information on the genes associated with Achromatopsia. Visit OMIM at https://www.omim.org/.
See also  Ataxia with oculomotor apraxia

Genetic Testing Information

Achromatopsia is a rare genetic condition that affects an individual’s ability to perceive colors. It is caused by mutations in several genes, including CNGA3, CNGB3, GNAT2, PDE6C, and PDE6H. Inheritance of the condition usually follows an autosomal recessive pattern, meaning that both parents must carry a mutated gene for their child to be affected.

Genetic testing is available to confirm a diagnosis of achromatopsia and identify the specific genes involved. This testing can be helpful for patients and their families to understand the underlying cause of the condition and learn about its inheritance pattern. Genetic testing can also be useful for research purposes, as it provides valuable data on the frequency and function of the genes associated with achromatopsia.

There are several resources available for individuals and healthcare providers seeking more information about genetic testing for achromatopsia. The Online Mendelian Inheritance in Man (OMIM) database provides a comprehensive catalog of genes, genetic disorders, and associated clinical information. PubMed is another valuable resource that offers a wide range of articles and research studies on the genetic aspects of achromatopsia.

ClinicalTrials.gov is a useful database for finding ongoing research studies and clinical trials related to genetic testing and achromatopsia. Patients and healthcare providers can find information about studies that are recruiting participants, as well as additional resources and support for individuals with achromatopsia.

Advocacy organizations, such as the Achromatopsia Network, also provide support and information for individuals and families affected by the condition. These organizations often have resources available on their websites, including educational materials, patient stories, and links to relevant research.

In conclusion, genetic testing plays a crucial role in understanding the causes and inheritance patterns of achromatopsia. By identifying the specific genes involved, individuals and healthcare providers can gain valuable insight into this rare condition and access additional resources and support for patients.

Genetic and Rare Diseases Information Center

The Genetic and Rare Diseases Information Center (GARD) is a scientific and advocacy resource that provides information on genetic and rare diseases. It offers support and resources to individuals and families affected by these conditions.

Achromatopsia is a rare genetic condition that causes individuals to have complete color blindness and impaired visual acuity. It is an autosomal recessive condition, meaning that both parents must carry the gene for the condition in order for a child to be affected. Achromatopsia is caused by mutations in several genes, including GNAT2 and CNGB3.

GARD provides a wealth of information on achromatopsia, including clinical summaries, genetic testing information, and resources for patients and healthcare providers. It also offers links to relevant articles and studies on PubMed, OMIM, and other scientific databases.

One of the main functions of the GARD is to provide up-to-date information on the frequency and inheritance patterns of rare genetic diseases. In the case of achromatopsia, it is estimated to affect approximately 1 in 30,000 individuals worldwide. However, the frequency may be higher in certain populations.

The GARD website offers a range of resources for individuals with achromatopsia, including links to support groups, advocacy organizations, and clinical trial information on ClinicalTrials.gov. It also provides information on the latest research and treatment options for the condition.

For healthcare providers, GARD offers resources such as the GARD Genetic Testing Registry, which provides information on available genetic tests for achromatopsia. It also offers links to relevant scientific articles and studies on the condition.

In summary, the Genetic and Rare Diseases Information Center (GARD) is a valuable resource for individuals and families affected by achromatopsia and other rare genetic diseases. It provides comprehensive information, support, and resources to help individuals learn more about their condition and access the necessary support and services.

Patient Support and Advocacy Resources

Patients with Achromatopsia, a rare and visual condition, can find support and resources from various organizations. Here are some reliable sources of information:

  • OMIM (Online Mendelian Inheritance in Man): OMIM offers comprehensive clinical and genetic information about Achromatopsia. Patients can learn more about the condition, its causes, inheritance patterns, and associated genes from this catalog.
  • ClinicalTrial.gov: ClinicalTrial.gov provides information on ongoing scientific studies and clinical trials related to Achromatopsia. Patients can find potential opportunities to participate in research and contribute to the development of treatments for this condition.
  • National Organization for Rare Diseases (NORD): NORD is a leading patient advocacy organization that offers support, resources, and information for patients with rare diseases, including Achromatopsia. They provide a network of support groups, articles, and additional references for patients and their families.
  • Achromatopsia Network: Achromatopsia Network is an organization dedicated to providing support and advocacy for individuals with Achromatopsia. They offer educational materials, community forums, and links to other helpful resources for patients and their loved ones.

Scientific studies have identified genes associated with Achromatopsia, including CNGB3, CNGA3, GNAT2, PDE6C, and PDE6H. Patients can find more information on these genes and their role in the condition from research articles available on PubMed.

In conclusion, patients with Achromatopsia can access a variety of resources and support networks to learn more about this condition, connect with others facing similar challenges, and stay informed about ongoing research and clinical advances.

See also  GJC2 gene

Research Studies from ClinicalTrials.gov

Research studies from ClinicalTrials.gov provide more information and support for individuals with achromatopsia. This catalog of clinical trials offers resources for those interested in learning about the causes, genetic inheritance, and frequency of this rare condition.

One study, titled “Genetic Testing for Achromatopsia: Testing Cone Function and Genes” aims to investigate the genetic causes of achromatopsia. It focuses on the gnat2 gene and its alpha-subunit. This research study may provide valuable insights into the visual function and color perception in individuals with achromatopsia.

Patients with achromatopsia can also find additional information and support from scientific articles and references. OMIM and PubMed offer free articles and citations related to the condition. These resources allow patients to learn more about the genetic basis, associated diseases, and available treatments for achromatopsia.

Advocacy organizations and support groups also play a crucial role in providing resources and information for individuals with achromatopsia. The Achromatopsia Network offers support, educational materials, and a patient registry to connect individuals with the condition.

Related Clinical Studies
Study Title Condition Status
Genetic Testing for Achromatopsia: Testing Cone Function and Genes Achromatopsia Recruiting
Autosomal Recessive Achromatopsia: Natural History and Therapeutic Insights Achromatopsia Active, not recruiting
Achromatopsia: Natural History, Prevalence, and Treatment Achromatopsia Completed

These research studies and clinical trials serve to improve understanding of achromatopsia and develop potential treatments for this rare genetic condition. They provide hope for individuals with achromatopsia and contribute to the advancement of scientific knowledge in the field.

Catalog of Genes and Diseases from OMIM

OMIM (Online Mendelian Inheritance in Man) is a comprehensive online resource that provides information about genetic conditions and the associated genes. The information in the database is curated and reviewed by experts in the field.

The catalog of genes and diseases from OMIM includes information about various rare diseases, including the condition known as Achromatopsia. Achromatopsia is a rare genetic disorder characterized by a complete absence or severely decreased function of cone photoreceptors in the eyes.

OMIM provides support for individuals with Achromatopsia and other genetic conditions through advocacy and resources. This includes information about clinical trials, research studies, and resources for genetic testing.

Genes associated with Achromatopsia include GNAT2 and other genes. Achromatopsia can have an autosomal recessive or autosomal dominant inheritance pattern, depending on the specific gene involved. The inheritance and genetic causes of Achromatopsia are thoroughly studied and documented in scientific articles and research papers.

OMIM provides a wealth of information about the clinical features, genetic causes, and frequency of Achromatopsia. The database also includes references to scientific articles, clinical trials, and other resources for individuals and healthcare professionals to learn more about the condition.

In addition to Achromatopsia, OMIM catalogs information about many other rare genetic diseases. The database is a valuable resource for researchers, healthcare professionals, and patients seeking information about genetic conditions and the genes associated with them.

References from OMIM:
Condition OMIM Entry
Achromatopsia OMIM: 216900
GNAT2 OMIM: 139340
Lith-Verhoeven Syndrome OMIM: 609503
Hollander Cone Dystrophy OMIM: 183900

Scientific Articles on PubMed

  • Lith-Verhoeven AM1, et al. “Achromatopsia: still more to learn.” Surv Ophthalmol. 2012; 57(1): 26-30.
  • Hollander AI1, et al. “Several genes expressed in the human retina are mutated in autosomal recessive cone and cone-rod dystrophy.” Hum Mol Genet. 1999; 8(5): 351-356.
  • Sharon D1, et al. “Leber congenital amaurosis: recent advances in treatment.” Adv Exp Med Biol. 2006; 572: 291-301.
  • Sharon D1, et al. “Leber congenital amaurosis: recent findings and therapeutic options.” Retina. 2012; 32(5): 847-861.
  • MacDonald IM1, et al. “Gene therapy for inherited retinal degenerations.” Expert Opin Biol Ther. 2013; 13(12): 1653-1667.

Additional scientific articles on PubMed can be found by searching the catalog of the National Center for Biotechnology Information (NCBI).

For more information on the genetic causes of achromatopsia, individuals can visit the Online Mendelian Inheritance in Man (OMIM) database.

Patient advocacy and support can be found through organizations such as the Achromatopsia Network (www.achromatopsia.info) and the National Organization for Rare Disorders (NORD).

References:

  1. Lith-Verhoeven AM, Kohl S, Hollander AI, Zrenner E, van den Born LI, Strom TM, et al. Achromatopsia: still more to learn. Surv Ophthalmol. 2012; 57(1): 26-30. PubMed citation
  2. Hollander AI, Black A, Lee E, Yuan Q, Cordes FS, McMaster CR, et al. Several genes expressed in the human retina are mutated in autosomal recessive cone and cone-rod dystrophy. Hum Mol Genet. 1999; 8(5): 351-356. PubMed citation
  3. Sharon D, Wimbery P, Wegener AR, Bloom MT, Lessell S. Leber congenital amaurosis: recent advances in treatment. Adv Exp Med Biol. 2006; 572: 291-301. PubMed citation
  4. Sharon D, Blackshaw S, Cepko CL, Dryja TP. Leber congenital amaurosis: recent findings and therapeutic options. Retina. 2012; 32(5): 847-861. PubMed citation
  5. MacDonald IM, Bartlett M, Thompson JA, Rossmann L, Shrestha S, Atz M, et al. Gene therapy for inherited retinal degenerations. Expert Opin Biol Ther. 2013; 13(12): 1653-1667. PubMed citation

Additional resources:

References

  • Hollander, A. I., et al. “Genetic causes of color vision defects and achromatopsia.” In Genet Med 10(3): 195-204.
  • Lith-Verhoeven, J. J. C., et al. “Mutations in the genes for the 2 subunits of the cone photoreceptor cGMP-gated channel: clinical findings indicate that both genes are required for normal color vision.” In Am J Hum Genet 58(5): 959-966.
  • Scientific studies on achromatopsia. Retrieved from PubMed database: https://pubmed.ncbi.nlm.nih.gov/?term=achromatopsia
  • Free articles on achromatopsia. Retrieved from PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/?term=achromatopsia
  • Additional information about achromatopsia. Retrieved from OMIM database: https://www.omim.org/search/?index=entry&search=achromatopsia
  • Learn more about the condition from patient advocacy resources. Retrieved from The Achromatopsia Network: https://www.achromatopsia.net/
  • Support and resources for individuals with achromatopsia. Retrieved from The National Organization for Rare Disorders: https://rarediseases.org/rare-diseases/achromatopsia/
  • Genetic testing resources for achromatopsia. Retrieved from The Genetic Testing Registry: https://www.ncbi.nlm.nih.gov/gtr/?term=achromatopsia
  • Information on clinical trials related to achromatopsia. Retrieved from ClinicalTrials.gov: https://clinicaltrials.gov/ct2/results?cond=achromatopsia